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Abstract 
Antiphospholipid syndrome (APS) is an autoimmune disease defined by the presence of 
arterial or venous thrombotic events and/or pregnancy morbidity in patients who test positive 
for antiphospholipid antibodies (aPL). APS can be isolated (known as primary APS) or 
associated with other autoimmune diseases, such as systemic lupus erythematosus (SLE; 
known as secondary APS). The kidney is a major target organ in APS and renal thrombosis 
can occur at any level within the vasculature of the kidney (renal arteries, intrarenal arteries, 
glomerular capillaries and renal veins);events reflect the site and size of the involved vessels. 
Histological findings vary widely, including ischaemic glomeruli and thrombotic lesions, 
without glomerular or arterial immune deposits on immunofluorescence. Renal prognosis is 
affected by the presence of aPL in patients with lupus nephritis and can be poor. In patients 
with SLE and aPL, biopsy should be performed because inflammatory and thrombotic lesions 
require different therapeutic approaches. Renal involvement in patients with definite APS is 
treated by anticoagulation with long-term warfarin. The range of renal manifestations 
associated with APS is broadening and, therefore, aPL has increasing relevance in end-stage 
renal disease, transplantation and pregnancy. 
 
 
Key points 
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by 
recurrent arterial or venous thrombosis and/or pregnancy morbidity and persistently 
elevated levels of antiphospholipid antibodies 
Renal involvement can be caused by thrombosis at any level within the vasculature of 
the kidney 
Clinical features include renal artery stenosis, renal infarction, renal vein thrombosis, 
thrombotic microangiopathy and hypertension 
Treatment of renal involvement in APS centres on anticoagulation with long-term 
warfarin 
Patients refractory to standard therapy with anticoagulation or who have catastrophic 
APS might benefit from targeted therapy, including the use of intravenous 
immunoglobulins, rituximab or eculizumab 
Introduction 
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by recurrent 
arterial or venous thrombosis and/or pregnancy-related problems and persistently elevated 
levels of antiphospholipid antibodies (aPL). Since the first detailed description of APS by 
Graham Hughes in 1983,1 this condition has become regarded as a crossroads of coagulation 
and the immune system. aPL comprise a heterogeneous group of antibodies that are directed 
against anionic phospholipids or protein–phospholipid complexes. Laboratory tests to 
identify aPL include solid-phase ELISA to detect antibodies against cardiolipin and 2- 
glycoprotein 1 (B2GPI) and functional assays, such as the lupus anticoagulant assay, that 
demonstrate the ability of aPL to prolong phospholipid-dependent clotting reactions. 
An international consensus statement on definitive classification criteria for APS was 
published in 1998,2 after a workshop in Sapporo, Japan, and was updated in 2006.3 At least 
one clinical manifestation, such as vascular thrombosis or pregnancy morbidity, together with 
two positive laboratory tests at least 12 weeks apart are required for diagnosis. APS alone is 
usually classified as primary APS; in the presence of other autoimmune disorders—especially 
systemic lupus erythematosus (SLE)—the condition is generally classified as secondary APS. 
(Figure 1) 
Evidence suggests that the prevalence of aPL in the general population is low.4,5 Standard 
techniques detect aPL in <1% of apparently healthy individuals and in up to 3% of the elderly 
population without clinical manifestations of APS.4 However, the prevalence of aPL is notably 
high in patients with thrombotic manifestations, such as at first stroke in people <50 years (10– 
26%) and in women with recurrent pregnancy loss (10–40%).6 In clinical practice, it is 
common to recognize patients with laboratory evidence of aPL . Among patients with SLE, 30–40% 
are positive for aPL.5,6 Of patients with both SLE and aPL, around half develop APS 
within 10–20 years.5 
Thrombotic events in patients with APS are most frequently observed in the deep veins of the 
lower limbs and the cerebral arterial circulation,7 but the kidney is also a major target organ 
(Box 1). Thrombosis can occur at any level within the vasculature of the kidney and the 
manifestations of thrombotic events reflect the sites and dimensions of involved vessels. 
Thus, aPL-related nephropathy warrants inclusion in the diagnosis of APS.8 In this Review, 
we describe the role of aPL antibodies in inducing renal disease and the clinical and 
histological features of APS involving the kidney. We also review the management of 
patients with renal involvement, including discussions of available and upcoming therapies. 
 
aPL and thrombosis 
In patients with circulating aPL, thrombotic events might but do not always occur, which 
suggests that the presence of aPL is necessary but not sufficient for thrombus formation in 
vivo. Rather, the theory that aPL creates a prothrombotic state that increases the risk of 
thrombotic events in the presence of another prothrombotic factor has been purported.9 The 
aPL-related prothrombotic state could be induced by many different pathophysiological 
mechanisms, such as cellular effects (on platelet membranes, endothelial cells and 
monocytes), increases in expression of plasma coagulation regulatory proteins (clotting 
components, such as antithrombin, protein C and protein S) and fibrinolysis.10 
The proposed pathophysiological mechanisms can be categorized into two types. Firstly, aPL 
might act in vivo by disrupting pro-coagulant and anticoagulant reactions occurring on cell 
membranes. Secondly, aPL might interact with specific cell-surface receptors (proteins, lipids 
or both) and induce signals downstream that will ultimately result in upregulation of cell-surface 
proteins.10 We and others have suggested that expression of tissue factor, the major 
coagulation initiator in vivo, by endothelial cells and monocytes is a leading mechanism 
contributing to thrombosis in APS.11 Several other processes have been related to aPLinduced 
thrombosis, such as conformational and post-translational redox modifications of 
B2GPI, decreased activity of endothelial nitric oxide synthase and complement activation. 
aPL can also cause direct or indirect cellular effects on endothelial cells, monocytes and 
platelets, mainly through binding to B2GPI expressed on cell membranes.10 Additionally, 
interaction of aPL with proteins implicated in clotting regulation—such as prothrombin, 
factor X, protein C and plasmin—might interfere with the inactivation of pro-coagulant 
factors and fibrinolysis. These interactions induce a prothrombotic and proinflammatory 
phenotype (Figure 2). 
Traditional cardiovascular risk factors, which are present in >50% of patients with APS,7 also 
frequently play an important part. For example, we have reported that arterial hypertension 
and hyperlipidaemia are independent risk factors for thrombotic events in patients with APS 
and aPL.12 
 
 
Clinical manifestations 
Any organ can be affected in patients with APS and, therefore, the range of clinical features 
is extremely wide. Vessels of all sizes can be affected by thrombus formation. The vascular 
pathological appearance is bland occlusion without inflammatory infiltrates in the wall of the 
vessels.13 
A wide spectrum of renal thrombotic effects have been described in association with aPL, 
such as renal artery stenosis, renal infarction, renal vein thrombosis and thrombotic 
microangiopathy (TMA).14,15 Besides TMA, various intrarenal vascular lesions have been 
described in primary APS,16 including APS nephropathy (also called aPL-associated 
nephropathy).17,18 The variety in clinical manifestations is reflected in the range of 
histological findings, and include ischaemic glomeruli and thrombotic lesions, without 
glomerular or arterial immune deposits on immunofluorescence.19 
 
APS nephropathy 
APS nephropathy is clinically characterized by a syndrome of vascular nephropathy 
associated with hypertension, acute or chronic renal insufficiency, proteinuria and inconstant 
haematuria that can present differently depending on the rapidity of onset. Acute presentation 
features TMA, whereas the chronic course favours histopathologically characterized arterial 
fibrous intimal hyperplasia, tubular thyroid-like appearance, arteriosclerosis, arteriolar 
occlusions and focal cortical atrophy.20 
Peculiar patterns of microscopic and ultrastructural findings are usually associated with 
TMA19 and manifest clinically as proteinuria, hypertension and renal impairment.15 
Proteinuria is generally mild, but might be in the nephrotic range).16–18 Thrombotic 
thrombocytopenic purpura and haemolytic uraemic syndrome, along with other disorders that 
feature TMA, should be ruled out,21 although differentiation can be challenging. Severe 
thrombocytopenia and microangiopathic anaemia are more commonly observed in 
thrombocytopenic purpura and haemolytic uraemic syndrome than in APS,15 whereas the 
presence of schistiocytes on blood smear is rarely observed in APS. A negative aPL test is 
also a valid tool to distinguish between APS and other possible causes of TMA.21 
Catastrophic should be ruled out, especially in patients who have thrombosis in multiple 
organs that develops over a short period of time.22 
Histological findings in APS neurophathy include distinctive microangiopathic features 
(focal and diffuse) that might affect any of the vessels within the intrarenal vasculature, 
including the glomeruli (Figure 3).1,15,16 In studies of kidney biopsy samples from patients 
with primary APS, Nochy and co-workers18 showed that all vaso-occlusive lesions were 
characterized by acute thrombosis (TMA) and chronic vascular lesions, such as fibrous 
intimal hyperplasia of interlobular arteries, recanalizing thrombi in arteries and arterioles, 
fibrous occlusions and focal cortical atrophy.18 Ultrastructural findings might include 
glomerular basement membrane reduplication associated with glomerular basement 
membrane wrinkling.15,16 Fakhouri and co-workers23 found evidence of glomerulonephritis in 
29 biopsy samples obtained from patients with primary APS without.23 Characteristic features 
of APS nephropathy were observed in 20 (69%) of specimens. Nevertheless, about one-third 
of the cases showed some pathological changes other than vascular APS nephropathy, such as 
minimal change disease, focal segmental glomerulosclerosis, membranous 
glomerulonephritis, mesangial C3 nephropathy and pauci-immune crescentic 
glomerulonephritis.23 In seven patients, the onset of the renal involvement was chronic or 
subacute.23 
Sinico and co-workers24 retrospectively studied 160 patients with primary APS and renal 
involvement was seen in 14 (9%). Renal biopsy samples were available for 10 patients. 
Histopathological changes included membranous glomerulonephritis in four, proliferative 
glomerulonephritis in two, TMA in two and vascular involvement as observed in chronic 
APS nephropathy in the remaining two cases. Membranous glomerulonephritis was 
characterized by immune deposits in the subepithelial area, mesangium and subendothelial 
space; C1q deposits, immunoglobulins and C3 were positive on testing. Two of four patients 
with membranous glomerulonephritis had low complement levels and one of these two was also 
positive for antinuclear antibodies. Moreover, two patients had diffuse proliferative 
glomerulonephritis resembling class IV lupus nephritis. The main histological picture, 
therefore, was membranous glomerulonephritis, whereas only four patients had histological 
lesions consistent with acute or chronic APS nephropathy. The association between aPL and 
membranous glomerulonephritis (class V) seems unclear, as it has been reported in some 
studies and anecdotal case reports,24–26 but not confirmed in others.17,27 
In 2002, Daugas et al.14 performed a retrospective study of 114 patients with lupus who had 
undergone renal biopsy. APS nephropathy was observed in 32% of patients with SLE, 
irrespective of lupus nephritis. APS nephropathy was significantly associated with lupus 
anticoagulant and extrarenal manifestations of APS (most frequently with arterial thrombosis 
and fetal loss). No association was found between APS nephropathy and venous thrombosis. 
Daugas and colleagues concluded that APS nephropathy was an independent risk factor for 
hypertension, elevated serum creatinine concentrations and increased interstitial fibrosis in 
SLE. 
In a large cohort of patient with SLE, Tektonidou et al.17 investigated prevalence, clinical 
associations and long-term outcomes of APS nephropathy. They diagnosed APS nephropathy 
in 32 (40%) of 81 patients with aPL, compared with only three (4%) of 70 without aPL. APS 
nephropathy was documented independently of lupus nephritis in approximately two-thirds of 
the patients with SLE with secondary APS. APS nephropathy was associated with the 
presence of lupus anticoagulant, antibodies against cardiolipin or both, but not with lupus 
nephritis. The authors concluded that among patients with SLE, APS nephropathy occurred 
almost exclusively in those with aPL. Patients with APS nephropathy developed 
hypertension, raised serum creatinine levels and histological progression of lesions, all of which are 
associated with poor renal outcomes. However, the frequency of renal 
insufficiency did not differ between patients with or those without APS nephropathy after 7 
years of follow-up monitoring.17 
 
Renal artery stenosis and thrombosis 
APS has been suggested as a rare cause of renal artery stenosis, which has important acute 
(renal infarction leading to ischaemic acute renal failure) and chronic (such as slowly 
progressive ischaemic renal failure) clinical consequences. Renovascular disease is also 
observed in some patients.20 
In 1990, Ostuni and colleagues28 reported a case of renal artery thrombosis in a patient with 
aPL. This association between aPL, arterial hypertension and renal artery stenosis was 
confirmed by other groups.29,30 Sangle et al.31 studied magnetic resonance angiography 
findings from patients with APS and resistant hypertension. Of 77 patients with APS and 
uncontrolled hypertension, 20 (28%) had imaging features consistent with renal artery 
lesions, which was notably higher than the rates in young hypertensive controls (8%) and 
healthy controls (3%). The most frequently reported pattern was smooth, delineated, 
generally noncritical stenosis distal to the ostium of the renal artery, although in some 
patients features consistent with atherosclerotic changes were noted. 
The most commonly observed clinical sign associated with renal artery thrombosis is newonset, 
often severe, hypertension or worsening of known systemic hypertension. Pain in the 
renal area, haematuria, or renal failure might be associated. The pathogenesis varies, ranging 
from in situ thrombosis of the renal arteries to embolization deriving from verrucous heart 
valve lesions.32 The diagnostic approach might differ depending on the severity of clinical 
presentation, but renal ultrasonography, abdominal CT, renal angiography, renal scintigraphy 
and gadolinium-enhanced magnetic resonance angiography have proved useful for diagnostic 
and prognostic purposes. 
 
Renal vein thrombosis 
Thrombosis of the renal vein has been observed in patients with different types of APS, such 
as aPL-positive patients with lupus nephritis and those with primary APS.20 Renal vein 
thrombosis might present with proteinuria, often in the nephrotic range, and this symptom 
can sometimes be the first clinical manifestation of the syndrome.1,33 Gluek and colleagues34 
reported in a large series of patients with SLE that the presence of lupus anticoagulant was 
strongly associated with renal thrombosis. Similarly, Asherson et al.35 showed an association 
between aPL and renal vein thrombosis in two patients with SLE who were positive for lupus 
anticoagulant and had proliferative lupus nephirits.35 
Nephrotic syndrome is rare in patients with primary APS but is more frequent in patients who 
have secondary APS concomitant with SLE. The renal vasculature should, therefore, be 
assessed with Doppler imaging to rule out renal vein thrombosis in aPL-positive patients who 
develop sudden severe proteinuria or acute impairment of renal function. Other conditions 
associated with the development of renal vein thrombosis should also be investigated, such as 
pregnancy and use of oral contraception. Renal vein thrombosis can complicate renal 
transplantation and affect outcomes, and these patients should receive special attention due to 
the increased risk of vaso-occlusive events.36 Contrast-enhanced CT and magnetic resonance 
angiography are valid tools to confirm renal vein thrombosis. 
 
Renal infarction 
Renal infarction might be associated with APS. In situ thrombosis, emboli from an upstream 
arterial lesion or a heart valve lesion can result in thrombotic events occurring in smalldiameter 
intraparenchymal vessels leading to renal infarction.2,18 
Symptoms at presentation of renal infarction include pain, hypertension (often severe) and 
impairment of renal function, and it might be one of the first features of APS. Multiple, often 
serious, thrombotic episodes have been described in some patients, mostly localized in the 
renal cortex.37,38 The most frequently observed histological findings are ischaemic features at 
the level of the glomerulus, tubular atrophy and interstitial fibrosis.20 Notably, Poux and coworkers 
39 reported that in five of eight patients with APS who underwent biopsy, no 
histological changes consistent with TMA were observed. Subclinical cases might be 
revealed by abdominal CT performed for other reasons32 but this can reveal scarring from an 
old silent infarct. Although renal infarction is not a classic clinical manifestation of APS, aPL 
testing should be performed in young people who present with this disorder39 to tailor 
treatment if necessary. Withdrawal of drugs, such as hydroxychloroquine, is potentially 
related to this rare complication.40 
 
Arterial hypertension 
Hypertension is associated with aPL and frequently presents with coexisting livedo 
reticularis.1 Arterial hypertension affects many patients with primary and secondary APS, and 
has been proposed as a sensitive sign of potential renal involvement. In a study of 16 patients 
with primary APS, Nochy et al.18 reported hypertension in 93% of 16 cases and noted that, in 
most, the condition was the only manifestation of possible kidney involvement. The high rate 
of hypertension is suggested to be due to severe vascular lesions, including fibrous intimal 
hyperplasia (in most of the cases), arteriosclerosis, arterial and arteriolar fibrous and 
fibrocellular occlusions and TMA.15,18 An analysis of 73 patients with borderline 
hypertension by Frostegard and co-workers41 showed higher titres of antibodies against 
B2GP1 in patients than in age-matched controls. The presence of IgG isotype antibodies 
correlated with plasma levels of insulin, insulin-like growth factor binding protein-1 and 
calculated insulin resistance, which suggests roles in both atherosclerosis and hypertension 
from the early stages onwards. Rollino and colleagues42 studied 26 patients with renal artery 
stenosis and 25 patients with severe essential hypertension (diastolic blood pressure >110 
mmHg or taking three or more hypertensive drugs) and compared them with 61 healthy 
controls matched for age and sex. Two (8%) of the 25 patients with severe essential 
hypertension had aPL compared with none of the controls. Several cases of malignant 
hypertension associated with aPL or in the context of APS have been described.43–45 Of note, 
systemic hypertension has been reported as a strong risk factor for thrombosis in patients with 
aPL, which suggests that careful blood pressure control is warranted in these patients.12,46 
Taken together, the evidence suggests that hypertension is a frequent manifestation of APS, 
but optimum management might be difficult to achieve. Control of arterial hypertension and 
anticoagulation when necessary (for example, in patients with histologically proven 
microthrombi) are thought to prevent progression to end-stage renal disease and future 
thrombosis.15 
 
Effects on lupus nephritis APS can affect the prognosis and renal outcomes in patients 
with lupus nephritis. Pérez Velásquez and colleagues47 reviewed a large cohort of patients 
with SLE (n = 600) and reported that among those with secondary APS, 56% had renal 
disease and, of those, 43% had typical features of APS on biopsy. Lupus anticoagulant and 
IgG antibodies against cardiolipin were more prevalent in these patients than in those without 
APS and they correlated with mortality.47 
Moroni and co-workers48 undertook a prospective study of 111 patients with lupus nephritis 
who were followed up for a mean of 14 years. 26% of the patients were positive for aPL, 
which was associated with increased incidence of thrombosis and pregnancy morbidity. A 
strong association between aPL and poor prognosis was also observed. Even after 
multivariate adjustment, the aPL remained associated with poor renal outcomes, high plasma 
creatinine levels at presentation and high chronicity index scores. These findings seem to 
support the role of aPL as an independent risk factor of chronic impairment of renal function 
in patients with SLE, but in other studies no such association has been found.49,50 
Tektonidou et al.17 evaluated the frequency of APS nephropathy in 151 patients with SLE 
who had undergone renal biopsy. APS nephropathy was independently related to lupus 
nephritis in about two-thirds of patients who had SLE and APS and in one-third of patients 
with SLE and aPL but not APS. By contrast, <5% of patients with SLE but without aPL had 
any histological signs of APS nephropathy. Indeed, APS nephropathy was associated with 
positive tests for lupus anticoagulant and antibodies against cardiolipin.17 The same study 
evaluated the progression of APS nephropathy through analysis of serial kidney biopsy 
findings. Evolution from acute thrombotic features to chronic thrombotic disease 
characterized by proliferative, obstructive and fibrotic lesions was found. If the first biopsy 
sample showed findings suggestive of TMA, chronic forms were frequently observed in the 
second or third biopsy specimens, for example, fibrous intimal hyperplasia, arteriolar 
occlusions, focal cortical atrophy or sclerotic features.17 Another study showed two distinct 
sets of findings for acute and chronic disease in biopsy specimens.51 Fibrin thrombi in 
interlobular arteries and involving glomerular arterioles were frequently found in samples 
from patients with acute renal episodes. In samples taken months or years later, chronic 
disease was characterized by arteries narrowed by recanalizing thrombi, ischaemic glomeruli 
with double contours and cellular or fibroelastic intimal proliferation. 
Coexisting APS nephropathy and lupus nephritis have been associated with poor renal 
outcome in some studies29,35 but not in others.52,53 In a cohort of 51 patients with SLE, the 
prevalence of crescents, sclerosis and glomerular necrosis was higher in patients with than in 
those without APS nephropathy which supports the concept that aPL and glomerular 
thrombosis are associated with poor renal outcomes.54 More patients with aPL had 
hypertension and raised creatinine levels than those without aPL, and were often associated 
with thrombosis (mainly arterial) during follow-up monitoring.17 In SLE patients with renal 
involvement, therefore, distinguishing between patients who have lupus nephritis (immunecomplex 
disease) and those who have impaired kidney function related to aPL (thrombotic 
events) is crucial to guide treatment.15 Immunosuppressive therapy is useful to treat lupus 
nephritis, whereas in patients with APS who have APS nephropathy lesions on renal biopsy, 
additional anticoagulation might be required.55 Patients with co-existing lupus nephritis and 
APS who test positive for lupus anticoagulant and have histological evidence of TMA, 
fibrous intimal hyperplasia or both are at increased risk of bleeding after renal biopsy.56 
These observations need confirmation, but they support testing for aPL in all patients with 
lupus nephritis before renal biopsy is performed. 
In summary, the prompt recognition of clinical and serological findings suggestive of renal 
involvement in patients with APS is crucial, and treating physicians should avoid postponing 
renal biopsy to ensure appropriate treatment is started early.32 
End-stage disease and transplantation Positive tests for aPL are more frequent among 
patients with end-stage renal disease than in the general population.57–59 aPL does not seem to 
be related to demographic features, such as age or sex, or to dialysis factors, including the 
duration of dialysis or the type of membrane used.55 Treatments or chronic viral hepatitis 
seem not to influence whether patients with end-stage renal disease have aPL.57,60,61 The 
mechanism underlying the association between aPL and end-stage renal disease remains 
unclear, although several have been proposed, including dialysis membranes,61 blood-cell 
activation during the haemodialysis circuit62 and the presence of microbial agents or their 
products (for example, endotoxins) in the dialysate.63 
Vaidya66 reported that 27 (3%) of 802 patients awaiting renal transplantation had APS. In two 
patients, post-transplant renal thrombosis was observed within 24 h despite warfarin therapy, 
which supports a potential pathogenic role for aPL in end-stage renal disease.66 Matsuda and 
co-workers64 demonstrated that antibodies against cardiolipin detected in patients undergoing 
dialysis seemed mostly to be B2GPI-independent.64 This finding suggests that the clinical 
value of measuring B2GPI-independent antibodies against cardiolipin is uncertain, as the 
precise risks for thrombosis associated with the presence of these antibodies in end-stage 
renal disease patients are not known.63,65 
Overall, however, the evidence is inconclusive with regards to pathogenic roles of aPL and 
antibodies against cardiolipin.66–71 In some studies, the presence of aPL was associated with 
an increased rate of haemodialysis-associated vascular access thrombosis.72–74 Whether 
measurement of antibodies against cardiolipin and of lupus anticoagulant should be 
considered separately remains uncertain, as whether they are equally associated with 
recurrent access thrombosis is unclear. Some studies report that both lupus anticoagulant and 
antibodies against cardiolipin increase the risk of vascular access thrombosis,74,75 but this 
association has been confirmed only for lupus anticoagulant.73,76 
End-stage renal disease is a rare complication of primary APS and only a few studies have 
investigated this relationship.24,40,77–79 The complication is particularly rare in paediatric 
patients.80 In a large retrospective study of 160 patients with primary APS, only one 
developed end-stage renal disease.24 Similarly, only one patient with end-stage renal disease 
was noted in a prospective study of 39 patients with primary APS.78 IgA antibodies against 
B2GPI in patients receiving haemodialysis have been suggested as an independent risk factor 
for mortality.81 The pathogenic role of the IgA isotype, however, remains unclear and studies 
are needed to investigate the clinical relevance of these antibodies.82 
Several studies investigating the clinical relevance of aPL in patients who underwent renal 
transplantation increased the risk of graft failure and thrombosis at any site within the renal 
vasculature.83–85 McIntyre and Wagenknecht86 reported that among 110 transplant recipients, 
those with aPL at the time of transplantation had a higher rate of early renal allograft failure 
than those without aPL. In patients who undergo renal transplantation, the frequency of aPL 
seems to be increased independently of the presence of SLE.87 57% of 56 patients who had 
early kidney allograft failure had aPL, compared with 35% of matched patients with 
functioning grafts.85 Biopsy samples from the aPL-positive patients with graft failure showed 
thrombotic features in nine and infarction in five.85 Indeed, anticoagulation does not 
completely abolish the risk of graft loss or thrombosis.88 Canaud et al.89 reviewed 1,359 
kidney transplantations performed in a single centre and found that at the time of 
transplantation, 37 (3%) patients had aPL. A notably high incidence of APS nephropathy was 
also observed in recipients positive for lupus anticoagulant. Furthermore, the presence of 
lupus anticoagulant was associated with accelerated progression of chronic vascular changes 
within the first year after transplantation. Biopsy analysis at 3 months and 12 months showed 
that progression of tubule-interstitial chronic lesions was delayed in relation to vascular 
lumen narrowing, which suggests a causal link between vascular damage and graft scars.89 
Other studies, however, have found no evidence of aPL as an independent risk factor for 
thrombosis after kidney transplantation. Fernández-Fresnedo and colleagues90 studied 197 
kidney grafts in cadavers of patients who had had functioning grafts for >1 year. Of these, 
27% had aPL before transplantation and 16% developed aPL after transplantation. The 
presence of aPL in the serum before transplantation was not associated with increased risk of 
post-transplant thrombosis. Furthermore, the development of aPL after transplantation was 
associated with acute rejection. 
Overall, the role of aPL in transplant recipients is still a matter of debate. However, the 
control of cardiovascular risk factors should be intensified in these patients if aPL are 
detected to reduce the risks of morbidity and transplant failure. 
 
Pregnancy 
Careful management of pregnancy in women with SLE and aPL is crucial from a 
nephrological standpoint. Pregnancy can influence SLE activity and lead to adverse effects 
on the kidneys in the short-term and long-term91 that might accelerate evolution to end-stage 
renal disease.92 Moreover, aPL-positive status is a well-documented risk factor for pregnancy 
morbidity, including recurrent miscarriage, premature delivery, intrauterine growth restriction 
and pre-eclampsia.3 
A possible link between hypertension and postpartum renal failure in pregnant women with 
SLE and aPL was purported by Kincaid-Smith and colleagues.51 Findings on renal biopsy 
were compatible with TMA, with fibrin thrombi present in glomeruli and arterioles, and were 
similar to those seen in thrombocytopenic purpura and haemolytic uraemic syndrome. Of 
note, these findings are also common in patients who present with malignant hypertension 
during treatment with oral contraceptives.32 A case of postpartum bilateral renal cortical 
necrosis in a woman with APS and SLE has also been reported.93 
The associations between aPL, renal involvement and pregnancy outcomes, however, remain 
poorly understood. A meta-analysis showed an association between aPL and hypertension in 
pregnant women, preterm delivery and recurrent miscarriages.91 The increased frequency of 
hypertension in women with APS might increase the risk of pre-eclampsia, which has a 
welldocumented 
association with APS.91 aPL is frequently found in patients with hypertension, 
independently of active lupus nephritis.91 
Women with aPL or SLE and aPL, irrespective of the presence of lupus nephritis, should be 
counselled before becoming pregnant about the impact of these antibodies on maternal and 
pregnancy outcomes. 
 
 
Catastrophic APS 
Catastrophic APS is a very severe variant of classic APS, and is characterized by acute 
clinically apparent multiple organ involvement, evidence of multiple small vessel occlusions 
on histopathology and usually a high titre of aPL. Although catastrophic APS is seen in <1% 
of all patients with APS, the condition is generally life threatening.22,94 Renal involvement is 
a common clinical feature of catastrophic APS.95 
Ischaemia of the bowels, lungs, heart and brain are most frequent, but rarely has adrenal, 
testicular, splenic, pancreatic or skin involvement been described. TMA is characteristic and 
leads to symptoms related to dysfunction of the affected organs. Precipitating factors of 
catastrophic APS include infections, surgical procedures, withdrawal of anticoagulant therapy 
and the use of oral contraceptives.96,97 
Tektonidou et al.98 compared histological renal biopsy findings for patients with catastrophic 
APS (n = 6), primary APS (n = 8) and secondary APS (with SLE; n = 23). Acute vascular 
lesions were documented in all patients with catastrophic APS and around one-third of 
patients with primary APS and secondary APS. Chronic changes were seen in two-thirds of 
patients in all APS groups. This study supports the observation that the main distinguishing 
feature between catastrophic and noncatastrophic APS is the higher frequency of the acute 
changes in the former. 
 
Treatment 
The treatment of patients with aPL without previous thrombotic events remains controversial. 
The current consensus is not to treat patients with low titres of aPL or with intermittent 
positivity of aPL.99 In patients with persistently medium to high titres of aPL, strict control of 
conventional risk factors for cardiovascular disease is essential Patients positive for multiple 
factors (lupus anticoagulant, as well as antibodies against cardiolipin and B2GPI) are at 
increased risk of thrombosis12,100,101 and might benefit from antiaggregation therapy. 
All patients with aPL should receive primary thromboprophylaxis with low-molecular-weight 
heparin in prothrombotic situations, such as surgery or immobilization. Some studies suggest 
use of hydroxychloroquine102,103 and statins101 in patients with persistently high titres of aPL. 
Treatment of APS with long-term warfarin for arterial or venous thrombosis is recommended 
(Box 2).99,104 Treatment with intermediate intensity warfarin (international normalized ratio 
2.0–3.0) is usually effective in patients after the first episode of venous thrombosis. Patients 
with arterial thrombosis or recurrent thrombotic events despite ongoing treatment might 
require higher intensity warfarin treatment (international normalized ratio 3.0–4.0). The use 
of an additional antiplatelet agent could be considered.99,104 
Renal artery stenosis can be managed with antihypertensive agents, antiplatelet drugs or 
anticoagulants.32 We analysed 14 hypertensive patients with APS and renal artery stenosis 
who received oral anticoagulation for >1 year. All patients benefited in terms of blood 
pressure and renal outcomes,32 which confirmed the finding of by Remondino and coworkers, 
105 who reported the recanalization of bilateral renal artery stenosis after 
anticoagulation treatment in a young woman with previously documented hypertension and 
APS. These observations support a role for anticoagulation in preventing the progression of 
these renal artery lesions.106 
A history of renal disease related to APS (especially renal impairment) is associated with 
complications during pregnancy and the puerperium. For these reasons, close 
multidisciplinary management, including obstetricians and nephrologists, is crucial to 
improve pregnancy outcomes.20 
Although corticosteroids, hydroxycloroquine107 and some immunosuppressive agents have 
occasionally been reported to reduce aPL titres,108 whether they have a role in reducing the 
risk of thrombosis is not proven. A few studies have been assessed the role of 
immunosuppressant agents in primary APS nephropathy and have reported favourable 
effects.109,110 Korkmaz et al.109 described four patients with primary APS with renal 
involvement who responded to steroids plus azathioprine or cyclophosphomide added to 
anticoagulation. Corticosteroids and other immunosuppressants, however, are not generally 
recommended for the treatment of APS. 
Patients with catastrophic APS are frequently treated with a combination of anticoagulants 
and corticosteroids plus intravenous immunoglobulin, and/or plasma exchange as first-line 
therapy.20 The use of cyclophosphamide, therefore, might be useful to treat catastrophic APS 
in patients with co-existing SLE .22 
Long-term intravenous immunoglobulin has been reported in a few cases of primary APS in 
which patients have relapsed despite standard treatment.111 New oral anticoagulants, such as 
dabigatran and rivaroxaban, are available. They have been efficacious in the management of 
venous thromboembolism and do not require laboratory monitoring. A trial of efficacy and 
safety of rivaroxaban in APS is under way.112 
B-cell depletion by treatment with rituximab has been suggested for use in selected cases of 
APS, mainly in those patients with severe thrombocytopenia.108 Erkan and co-workers113 
conducted a 12-month, phase II pilot study of rituximab, including adult patients with aPL 
and non-criteria APS manifestations. One patient was diagnosed as having nephropathy and 
achieved partial remission with no recurrence after two doses of 1,000 mg rituximab on day 1 
and day 15. Other targeted therapies have been efficacious in experimental models of APS.114 
For example, acute recurrence of TMA after renal transplantation was successfully treated 
with eculizumab and antibodies against C5, which suggests that such therapy could be 
beneficial in patients with fulminant recurrence of TMA after kidney transplantation resistant 
to classical therapy.115 
Future studies exploring the mechanisms of aPL in inducing the clinical manifestations 
associated with APS will be useful in the design of further tailored approaches. 
 
Conclusions 
The kidney is a major target organ in primary and secondary APS. Renal involvement is a 
well-recognized manifestation of the syndrome and is characterised by thrombosis that can 
affect any vascular site in the kidneys. Treatment of renal involvement in patients with 
definite APS involves long-term anticoagulation with warfarin. New oral anticoagulants have 
been developed for clinical use and a trial to assess the efficacy and safety of rivaroxaban in 
APS is ongoing. Other therapeutic approaches might be useful in refractory cases, including 
the use of intravenous immunoglobulins, rituximab or eculizumab. Future studies need to 
focus on the pathogenesis of APS, which might yield potential targets for treatment, such as 
tissue factor pathway and complement factor inhibitors. A compelling need exists for trials 
aimed at improving clinical outcomes in APS and attempting to solve the crucial issues, such 
as reducing the thrombotic risk in patients with aPL or tailored approaches in refractory 
cases. 
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Figure 1 Venn diagram of the clinical presentation of APS. APS alone is usually classified as 
primary APS and, in the presence of SLE or another autoimmune disorder, is classified as 
secondary APS. This distinction is mainly for research and classification purposes, although 
there seem to be few differences in complications and antibody specificity. Most patients 
with primary APS do not progress to SLE. Abbreviations: aPL, antiphospholipid antibody; 
APS, antiphospholipid syndrome; APSN, APS-associated nephropathy; CAPS, catastrophic 
APS. 
 
 
 
Figure 2 Pathophysiological mechanisms of thrombogenesis induced by antiphospholipid 
antibodies. A two-stage process is purported whereby aPL creates a prothrombotic state that 
increases the risk of thrombotic events in the presence of another prothrombotic factor 
Abbreviations: aPL, antiphospholipid antibodies; ROS, reactive oxygen species; TF, tissue 
factor; TH, T-helper cell; TNF, tumour necrosis factor. 
 
 
 
 
 
 
 
 
Figure 3 Histological characterization of APS-associated nephropathy. a | Haematoxylin and 
eosin stain showing two glomeruli, one of which (right) contains intracapillary thrombi 
(white arrows). The afferent arteriole of the glomerulus on the left is entirely occluded by a 
fibrin thrombus (black arrow). b | Haematoxylin and eosin stain showing fibrinoid necrosis 
and mucoid intimal oedema in the intima of an arteriole (red arrow) with fragmented red 
blood cells. The interstitium around the arteriole is oedematous. c | Haematoxylin and eosin 
stain showing thrombi occluding peritubular capillaries (black arrow). Interstitial oedema, 
haemorrhage and acute tubular injury might be present dependent on the severity of acute 
ischemic injury. d | A large intravascular thrombus at the vascular pole of a glomerulus 
stained red with trichrome staining (black arrow). e | Direct immunofluorescence also shows 
positive staining for fibrinogen in glomerular capillary lumina and at the vascular pole (white 
arrows). f | On ultrastructural analysis fibrin can be seen occluding the capillary lumen. 
Endothelial cells have lost fenestration and podocytes reveal extensive foot process 
effacement. g | In chronic disease, double contours without interposition of electron dense 
immune-complexes can be seen (white arrows). Platelets are seen in capillary lumina in both 
acute and chronic phases (black circle). Podocytes are often injured and reveal foot process 
effacement (black arrows). Permission to reproduce obtained from L. Barisoni, Department 
of Pathology, Division of renal pathology, University of Miami, Miller School of Medicine, 
Miami, FL, USA 
 
Box 1 | Renal involvement in antiphospholipid syndrome 
Antiphospholipid syndrome nephropathy 
Renal artery stenosis and thrombosis 
Renal vein thrombosis 
Renal infarction 
Systemic hypertension 
Glomerular microthrombosis in lupus-associated nephritis related to antiphospholipid 
antibodies 
Catastrophic antiphospholipid syndrome 
 
Box 2 | Primary and secondary thromboprophylaxis in patients with aPL* 
Primary thromboprophylaxis 
Patients with primary APS and aPL 
Control of cardiovascular risk factors, especially in patients with high-risk aPL 
profiles (for example, positive for aCL, aB2GPI and LA) 
Long-term prophylaxis with low-dose aspirin is suggested in patients with a high-risk 
aPL profiles, especially in the presence of other cardiovascular risk factors 
Prophylaxis with LMWH in high-risk prothrombotic situations (for example, surgery, 
long-term immobilization and puerperium) 
Patients with aPL and concomitant autoimmune disease (for example, SLE) 
Hydroxychloroquine, with or without low-dose aspirin 
Secondary thromboprophylaxis 
Definite APS and a first venous event 
Warfarin to a target INR of 2.0–3.0 
Definite APS and arterial thrombosis 
Warfarin to a target INR of 3.0–4.0 
Kidney involvement 
Renal artery stenosis 
Antihypertensive agents, antiplatelet drugs, or anticoagulants have been reported to be 
efficacious 
APS patients with APS nephropathy lesions on renal biopsy 
Anticoagulants Catastrophic APS 
combined anticoagulants and corticosteroids plus intravenous immunoglobulin, 
plasma exchange or both 
The use of cyclophosphamide might be considered in patients with co-existing SLE 
Therapy duration 
Patients with definite APS and thrombosis 
Indefinite therapy with warfarin 
Cases of first venous event, non-high-risk aPL profile and a known precipitating factor (for 
example, oral contraceptive pill) 
Anticoagulants for a maximum of 6 months 
Refractory or difficult cases (difficult INR control, bleeding or major bleeding risk) 
Alternative therapies could be explored, including long-term LMWH, hydroxychloroquine, 
statins or biological therapy (for example, rituximab), but no data from clinical trials prove 
the efficacy of these drugs 
*Recommendations based on Ruiz-Irastorza et al.99 Abbreviations: aBGPI, antibodies against β2- 
glycoprotein I; aCL, antibodies against cardiolipin; AL; aPL, antibodies against phospholipid; APS, 
antiphospholipid syndrome; INR, international normalized ratio; LMWH, low-molecular-weight 
heparin; SLE, systemic lupus erythematosus 
